A Pharmacodynamic Comparison of Prasugrel vs. Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease

Trial Profile

A Pharmacodynamic Comparison of Prasugrel vs. Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Oct 2016

At a glance

  • Drugs Prasugrel (Primary) ; Ticagrelor (Primary)
  • Indications Thrombosis
  • Focus Pharmacodynamics
  • Acronyms OPTIMUS-4
  • Most Recent Events

    • 24 Aug 2016 Primary endpoint (Platelet reactivity) has been met according to the results published in the Circulation.
    • 24 Aug 2016 Results published in the Circulation
    • 01 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top